Sarmistha Nanda

1.3k total citations
18 papers, 571 citations indexed

About

Sarmistha Nanda is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sarmistha Nanda has authored 18 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sarmistha Nanda's work include HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Advanced Breast Cancer Therapies (5 papers). Sarmistha Nanda is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Advanced Breast Cancer Therapies (5 papers). Sarmistha Nanda collaborates with scholars based in United States, Italy and India. Sarmistha Nanda's co-authors include Rachel Schiff, Martin J. Shea, Tamika Mitchell, Naomi J. Halas, Amit Joshi, Alexander S. Urban, Ciceron Ayala‐Orozco, Sandra Whaley Bishnoi, Mark W. Knight and Amanda M. Goodman and has published in prestigious journals such as ACS Nano, Cancer Research and Diabetes.

In The Last Decade

Sarmistha Nanda

17 papers receiving 569 citations

Peers

Countries citing papers authored by Sarmistha Nanda

Since Specialization

Citations

This map shows the geographic impact of Sarmistha Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarmistha Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarmistha Nanda more than expected).

Fields of papers citing papers by Sarmistha Nanda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarmistha Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarmistha Nanda. The network helps show where Sarmistha Nanda may publish in the future.

Co-authorship network of co-authors of Sarmistha Nanda

This figure shows the co-authorship network connecting the top 25 collaborators of Sarmistha Nanda. A scholar is included among the top collaborators of Sarmistha Nanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarmistha Nanda. Sarmistha Nanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2‐positive breast cancer 2025 ·British Journal of Pharmacology ·(unknown), Raksha R. Bhat, (unknown), (unknown), Suhas Vasaikar, Sarmistha Nanda, (unknown), Martin J. Shea, Wangjia Cao, Jamunarani Veeraraghavan, Hee‐Yong Kim, Tasneem Bawa‐Khalfe, Tahir Hussain, Xinli Liu, Preethi H. Gunaratne, Rachel Schiff, Meghana V. Trivedi	2
2	SMedia: social media data analysis for emergency detection and its type identification 2023 ·International Journal of Computational Science and Engineering ·Sarmistha Nanda, Chhabi Rani Panigrahi, Bibudhendu Pati, Prasant Mohapatra	0
3	NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer 2022 ·Scientific Reports ·Raksha R. Bhat, (unknown), (unknown), Suhas Vasaikar, Carmine De Angelis, (unknown), Maria Letizia Cataldo, Sarmistha Nanda, Xiaoyong Fu, Bing Zhang, Rachel Schiff, Meghana V. Trivedi	10
4	Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models 2022 ·Cancer Research ·(unknown), (unknown), (unknown), Sarmistha Nanda, Lanfang Qin, Pier Selenica, Andrea Gazzo, Yingjie Zhu, Michael A. Mancini, Fabio Stossi, Irmina Diala, Lisa D. Eli, Britta Weigelt, Jorge S. Reis‐Filho, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff, Jamunarani Veeraraghavan	1
5	Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications 2022 ·Cancer Research ·Jamunarani Veeraraghavan, (unknown), (unknown), Pier Selenica, Sarmistha Nanda, Lanfang Qin, Yingjie Zhu, Juber Patel, Andrea Gazzo, Fabio Stossi, Michael A. Mancini, Carolina Gutiérrez, Britta Weigelt, Jorge S. Reis‐Filho, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff	1
6	Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer 2022 ·Cancer Research ·Jamunarani Veeraraghavan, (unknown), (unknown), Pier Selenica, Sarmistha Nanda, Lanfang Qin, Andrea Gazzo, Yingjie Zhu, Michael A. Mancini, Fabio Stossi, Britta Weigelt, Jorge S. Reis‐Filho, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff	3
7	A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer 2021 ·The FASEB Journal ·(unknown), Raksha R. Bhat, Lanfang Qin, Suhas Vasaikar, (unknown), Tamika Mitchell, Martin J. Shea, Sarmistha Nanda, (unknown), Bing Zhang, Carmine De Angelis, Rachel Schiff, Meghana V. Trivedi	16
8	Abstract 1077: Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models 2021 ·Cancer Research ·Jamunarani Veeraraghavan, (unknown), Sarmistha Nanda, (unknown), (unknown), Vidyalakshmi Sethunath, Martin J. Shea, Tamika Mitchell, Meenakshi Anurag, Michael A. Mancini, Irmina Diala, Alshad S. Lalani, Fabio Stossi, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff	1
9	Abstract PD3-09: HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models 2021 ·Cancer Research ·Jamunarani Veeraraghavan, (unknown), Sarmistha Nanda, Vidyalakshmi Sethunath, Martin J. Shea, Tamika Mitchell, Meenakshi Anurag, Michael A. Mancini, Fabio Stossi, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff	3
10	Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer 2021 ·Cancer Research ·Xiaoyong Fu, Resel Pereira, Lanfang Qin, Carmine De Angelis, Sarmistha Nanda, Martin J. Shea, Agostina Nardone, Rinath Jeselsohn, Ofir Cohen, Nikhil Wagle, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff	2
11	Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models 2020 ·Cancer Research ·Jamunarani Veeraraghavan, (unknown), Sarmistha Nanda, Vidyalakshmi Sethunath, Martin J. Shea, Tamika Mitchell, Meenakshi Anurag, Michael A. Mancini, Fabio Stossi, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff	10
12	Abstract 1926: Npy1r as a prognostic marker and a novel drug target in estrogen receptor-positive breast cancer 2018 ·Cancer Research ·Raksha R. Bhat, Suhas Vasaikar, (unknown), (unknown), Maria Letizia Cataldo, Sarmistha Nanda, Bing Zhang, Rachel Schiff, Meghana V. Trivedi	1
13	GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer 2018 ·Breast Cancer Research and Treatment ·Raksha R. Bhat, (unknown), Debashish Sahay, (unknown), Chad J. Creighton, (unknown), (unknown), Vikas Yadav, Lanfang Qin, Sarmistha Nanda, Vidyalakshmi Sethunath, Xiaoyong Fu, Carmine De Angelis, Vihang A. Narkar, C. Kent Osborne, Rachel Schiff, Meghana V. Trivedi	22
14	Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance 2014 ·Breast Cancer Research and Treatment ·Gladys Morrison, Xiaoyong Fu, Martin J. Shea, Sarmistha Nanda, Mario Giuliano, Tao Wang, Teresa Klinowska, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff	39
15	Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors 2014 ·Journal of Controlled Release ·Ciceron Ayala‐Orozco, (unknown), Sandra Whaley Bishnoi, Alexander S. Urban, (unknown), Tamika Mitchell, Martin J. Shea, Sarmistha Nanda, Rachel Schiff, Naomi J. Halas, Amit Joshi	71
16	Au Nanomatryoshkas as Efficient Near-Infrared Photothermal Transducers for Cancer Treatment: Benchmarking against Nanoshells 2014 ·ACS Nano ·Ciceron Ayala‐Orozco, (unknown), Mark W. Knight, Alexander S. Urban, Oara Neumann, Sandra Whaley Bishnoi, Shaunak Mukherjee, Amanda M. Goodman, (unknown), Tamika Mitchell, Martin J. Shea, (unknown), Sarmistha Nanda, Rachel Schiff, Naomi J. Halas, Amit Joshi	327
17	Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors 2012 ·Cancer Research ·Xuebin Fu, Varun Kumar, (unknown), (unknown), Sarmistha Nanda, (unknown), Tamika Mitchell, (unknown), (unknown), Ayesha R. Joshi, (unknown), (unknown), (unknown), (unknown), C. Kent Osborne, Rachel Schiff	1
18	BETA2 Activates Transcription From the Upstream Glucokinase Gene Promoter in Islet β-Cells and Gut Endocrine Cells 2003 ·Diabetes ·J. Michael Moates, Sarmistha Nanda, Michelle A. Cissell, Ming‐Jer Tsai, Roland Stein	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact